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Pulmonary arterial hypertension (PAH) has demonstrated multi-serotonin receptor
dependent pathologies, characterized by increased tone (5-HT1B receptor) and complex
lesions (SERT, 5-HT1B, 5-HT2B receptors) of the pulmonary vasculature together with
right ventricular hypertrophy, ischemia and fibrosis (5-HT2B receptor). Selective inhibitors
of individual signaling elements – SERT, 5-HT2A, 5HT2B, and combined 5-HT2A/B
receptors, have all been tested clinically and failed. Thus, inhibition of tryptophan
hydroxylase 1 (TPH1), the rate limiting step in 5-HT synthesis, has been suggested as
a more broad, and thereby more effective, mode of 5-HT inhibition. However, selectivity
over non-pathogenic enzyme family members, TPH2, phenylalanine hydroxylase, and
tyrosine hydroxylase has hampered therapeutic development. Here we describe the
site/sequence, biochemical, and biophysical characterization of a novel allosteric site on
TPH1 through which selectivity over TPH2 and related aromatic amino acid hydroxylases
is achieved. We demonstrate the mechanism of action by which novel compounds
selectively inhibit TPH1 using surface plasma resonance and enzyme competition
assays with both tryptophan ligand and BH4 co-factor. We demonstrate 15-fold greater
potency within a human carcinoid cell line versus the most potent known TPH1/2 non-
specific inhibitor. Lastly, we detail a novel canine in vivo system utilized to determine
effective biologic inhibition of newly synthesized 5-HT. These findings are the first to
demonstrate TPH1-selective inhibition and may pave the way to a truly effective means
to reduce pathologic 5-HT and thereby treat complex remodeling diseases such as PAH.
Keywords: serotonin, tryptophan, allosteric binding, pulmonary arterial hypertension
Abbreviations: 5-HT, 5-hydroxytryptamine; BH4, tetrahydrobiopterin; HTAB, hexadecyltrimethylammonium bromide;
PAH, pulmonary arterial hypertension; pCPA, p-chlorophenylalanine; PH, phenylalanine hydroxylase; SERT, serotonin
transporter; TPH, tryptophan hydroxylase; TH, tyrosine hydroxylase.
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INTRODUCTION
Serotonin (5-HT) has 15 receptors (5-HTR) divided into
seven families, whose wide distribution and function both
peripherally and within the central nervous system indicate the
complexity of this signaling system (Berger et al., 2009). Despite
this complexity, effective therapeutics of serotonin signaling
have been developed; SERT antagonists for the treatment
of depression (Stahl et al., 2013); 5-HT1 receptor isoform
agonists for migrane headaches (Derry et al., 2014); 5-HT2A
receptor inhibitors as atypical anti-psychotics (Werner and
Covenas, 2014); 5-HT3 receptor inhibitors for the treatment of
chemotherapy-induced vomiting and irritable bowel syndrome
(Cremonini et al., 2012). However, diseases characterized by
more complex pathophysiology involving multiple elements of
the 5-HT signaling cascade have failed to respond to selective
receptor therapies.
Pulmonary arterial hypertension has demonstrated multi-
serotonin receptor pathologies, characterized by increased tone
(5-HT1B receptor) and complex lesions (SERT, 5-HT1B, 5-HT2B
receptors) of the pulmonary vasculature together with right
ventricular hypertrophy, ischemia and fibrosis (5-HT2B receptor)
(Thomas et al., 2013). Inhibitors of SERT (Shah et al.,
2009), 5-HT2A (Frishman et al., 1995), 5-HT2B (Tomillero
and Moral, 2008), and combined 5-HTR2A/B (Dumitrascu
et al., 2011) receptors have all been tested clinically and
failed. Furthermore, carcinoid syndrome, in which carcinoid
tumor metastases in the lung over-produce 5-HT (avoiding
hepatic degradation) presents as a broad array of symptoms
through several 5-HT receptors – nausea/vomiting, diarrhea
(5-HT3 receptor), bronchoconstriction (5-HT1B/2A receptors),
right heart fibrosis (5-HT2B receptor) (Druce et al., 2009).
As with pulmonary endothelium in PAH, carcinoid tumors
produce large amounts of 5-HT through the over-expression
TPH1 – the rate limiting step in 5-HT synthesis (Lovenberg
et al., 1967). Pre-clinical data in models of PAH using
either siRNA blockade of TPH1 or therapeutic inhibition
via the low molecular weight compound pCPA has shown
profound effects on both vasoactive and remodeling disease
indices (Morecroft et al., 2012). However, the therapeutic
potential of pCPA is limited by additional activity on other
aromatic amino acid hydroxylases (tyrosine and PH) and the
alternative TPH isoform TPH2. The two TPH1 isoforms differ
in distribution, with TPH1 responsible for peripheral 5-HT
synthesis whereas TPH2 predominates in the brainstem, and
is thus responsible for the majority of behavior-related 5-HT
production and subsequent signaling (5-HT does not cross
the blood brain barrier) (Walther et al., 2003). Early clinical
data in carcinoid syndrome using pCPA revealed the liabilities
of non-selective TPH inhibition, where TPH2 inhibition has
been retrospectively attributed to psychosis observed in some
patients (Engelman et al., 1967). More recent molecules such
as Telotristat etiprate, which more potently inhibits TPH1/2
than pCPA, with better selectivity over related aromatic amino
acid hydroxylases, have demonstrated efficacy in carcinoid
syndrome trials showing some symptomatic improvements and
good tolerability (Kulke et al., 2014). The distribution and
activity of telotristat etiprate is predominantly gut restricted
(Shi et al., 2008; Kim et al., 2015) - the principal site of
physiologic TPH1 activity/5-HT production – avoiding the
adverse effects of TPH2-mediated 5-HT production in the CNS
and consequent psychiatric toxicity. However, the efficacy of such
a therapeutic strategy is limited in diseases where the principal
site of pathologic 5-HT production is distal to the gut, such as
pulmonary endothelium in PAH or lung metastases in carcinoid
syndrome.
Thus it is clear that there is a need for peripherally acting
inhibitors of TPH1 with selectivity over TPH2. The high
degree of homology between the isoforms (71% amino
acid identity) and identical orthosteric site binding residues
(Walther and Bader, 2003; Walther et al., 2003) make gaining
selectivity an extreme medicinal chemistry challenge. Platelet
storage of synthesized 5-HT also represents a challenge
for biology in demonstrating inhibition of TPH1 activity
in vivo. Here we describe the biochemical and biophysical
characterization of a novel allosteric site on TPH1 through
which selectivity over TPH2 is achieved and demonstrate the
mechanism of action of compound inhibition. We describe
the evolving potency and selectivity of TPH1-selective
compounds, which originate from a novel high-throughput
proximity assay screen. Furthermore, we detail novel in vitro
and in vivo systems utilized to determine effective biologic
inhibition of newly synthesized 5-HT by a novel antagonist
series.
MATERIALS AND METHODS
In Vitro TPH Activity Assays
Human TPH-1 and Human TPH-2 enzyme assays were carried
out at room temperature with atmosphere oxygen in a volume
of 25 µL. A base buffer of 40 mM HEPES pH 7.0, 200 mM
ammonium sulfate was made and stored at 4◦C. On the
day of assay, final concentrations of 10 µM iron ammonium
sulfate, 0.1 mg mL−1 BSA, 25 µg mL−1 catalase, and 0.04%
Chaps were added and designated as enzyme buffer. Substrate
buffer was made the same way but for the addition of a final
concentration of 10 mM DTT. Enzymes were diluted as follows:
1.25x = 12.5 nM TPH1 (Final = 10 nM) or 1.25x = 37.5 nM
TPH2 (Final= 30 nM) in enzyme buffer. Substrates were diluted
as follows: 5x = 200 µM (6R)-5,6,7,8-Tetrahydrobiopterin
dihydrochloride (BH4) (Final = 40 µM) and 5x = 100 µM
Tryptophan (Final = 20 µM) in substrate buffer. Compounds
were serially diluted 1:1 in DMSO to 50x = 500 µM
(Final = 10 µM). Assays were performed in GNF Custom
Greiner Black 384-well plates. Compounds were added at 0.5 µL
per well. Enzymes were added at 20 µL per well. Compounds
and enzymes were pre-incubated 15 min at room temperature.
Substrates were added at 5 µL per well to initiate the reaction.
The plates were covered and incubated at room temperature:
30 min for TPH1 and 60 min for TPH2. The reactions were
quenched with the addition of 25 µL 30% sulfuric acid. The plates
were read immediately with a PerkinElmer Envision reader at
excitation= 280 and emission= 535.
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Protein Preparation and X-ray
Crystallography
Escherichia coli BL21 Rosetta (DE3) cells harboring a plasmid
encoding human TPH1 (amino acid residues 103–413 or residues
104–394) with N-terminal His6-tag were grown in a bio-reactor
in auto induction medium. The constructs TPH1 (103–413)
and TPH1 (104–394) were used for x-ray crystallization and
SPR experiments, respectively (equivalent biochemical activity
demonstrated – data not shown). Frozen cell pellets were
homogenized in 50 mM Tris-HCl (pH 8.0), 400 mM NaCl, 1 mM
tris(2-carboxyethyl)phosphine (TCEP), 5% glycerol, 0.1% 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate and
the protease inhibitor cocktail complete/EDTA free (Roche) and
cells were lyzed with a microfluidizer. The protein was purified
by Ni-NTA (Qiagen). The His6-tag was removed with HRV 3C
protease cleavage followed by size exclusion chromatography
(Superdex SPX200/16/60; GE Healthcare), using MES 25 mM,
pH 6, NaCl 100 mM, Glycerol 5%, Methionine 3 mM,
TCEP 2 mM as elution buffer. For crystallization purposes,
the protein was concentrated to 10 mg ml−1. The resulting
protein was estimated to be >95% pure and homogeneous by
SDS-PAGE and reverse phase HPLC. The identity of the protein
was further confirmed by N-terminal sequencing and mass
spectrometry (Q-Tof, Micromass, Waters). Structural location
diagrams were generated using Molsoft ICMPro modeling tool.
Protein sequence alignment was enabled by RCSB protein
databank and EMBL Cluster Omega analysis.
Biacore
Biosensor experiments were performed on a Biacore T100
instrument (GE Healthcare). Biotinylation and capture of TPH1
was performed by adding a volume of freshly prepared EZ-link
solution (dissolved in water) to an aliquot of TPH1(104–394)
in a 2:1 molar ratio and incubated on ice. After 30 min of
incubation, the reaction was stopped by the addition of 100 mM
of Tris pH7.5. Unreacted biotin was removed by passing the
solution over a fast desalting column (Thermo scientific #89849,
equilibrated with PBS, 0.5 mM TCEP) three times. Biotinylated
protein was aliquoted and kept at −80◦C until use. Biotinylated
TPH1 (104–394) was immobilized at 22◦C on a SA chip surface
(GE Healthcare) equilibrated with 10 mM Hepes, 150 mM NaCl,
1 mM TCEP, 0.05% Tween20, 5% glycerol, pH7.6. Approximately
3200RU were immobilized using this procedure. A streptavidin
surface served as the reference.
Binding experiments were performed at 20◦C using 10 mM
Hepes, 150 mM NaCl, 1 mM TCEP, 0.05% Tween20, 5% glycerol,
pH7.6, 2% DMSO as running buffer. To match precisely the
DMSO concentration of the analytes and the running buffer
all analytes were first prepared as a 100x stock in DMSO, then
1 ml analyte1 +1 ml analyte2 (or 1 ml DMSO) + 98 ml of
10 mM Hepes, 150 mM NaCl, 1 mM TCEP, 0.05% Tween20,
5% glycerol, pH7.6 were mixed to keep a final DMSO content of
2% in each sample. Using a flow rate of 50 ml min−1, samples
were injected for 120 s and dissociation was monitored for
240 s. The data collection rate was 10 Hz. As a preliminary
experiment, all analytes were run in a 8-point dose response
mode under the conditions mentioned above to determine their
affinity toward TPH1 (data not shown). Concentrations used
for competition experiments were subsequently chosen around
5–10x the KD for each individual analyte (10 mM of NVS-
TPH146 and 100 mM LP533401) and 2x the KD for L-Trp
(100 mM). In supplementary studies investigating the relative
binding characteristics versus BH2 co-factor and combination
with L-Trp ligand, concentrations used were 5 mM for NVS-
TPH146 and 100 mM for both BH2 and L-Trp (KD previously
estimated to 11 and 56 mM, respectively, data not shown).
Mode of Inhibition Studies
Mode of inhibition studies were performed in triplicate using
the primary screen assay with varying concentrations of the
substrate at fixed concentrations of inhibitor. For looking at
the dependency of inhibition with tryptophan, BH4 was held
at a fixed concentration of 10 µM and for looking at the
dependency with BH4, tryptophan was held at a concentration
of 10 µM. Reaction rates were monitored at fixed time points
for up to 30 min and converted using a standard curve for 5-
hydroxytryptophan. Slopes were subsequently calculated from
the linear portions of the converted progress curves. The data
was fitted globally to the equations describing competitive, non-
competitive, mixed, and uncompetitive inhibition models (as
described below) and best fit analysis was carried out using the
Enzyme Kinetics module of SigmaPlot (V12.1).
Competitive (Full) :
v = Vmax (1+ (Km S−1)∗(1+ I Ki−1))−1
Competitive (Partial) :
v = Vmax (1+ (Km S−1)∗(1+ I Ki1−1)(1+ I Ki2−1)−1)−1
Noncompetitive (Full) :
v = Vmax ((1+ I Ki−1)∗(1+ Km S−1))−1
Noncompetitive (Partial) :
v = Vmax ((1+ Km S−1)∗(1+ I Ki−1)(1+ I∗beta Ki−1)−1)−1
Mixed (Full) :
v = Vmax ((Km S−1)∗(1+ I Ki−1)+ (1+ I (alpha∗Ki)−1))−1
Novel Cell Assay Assessment of TPH1
Activity
5-HT newly synthesized through TPH activity was assessed both
in vitro and in vivo by addition of deuterium labeled substrate
(deuterated tryptophan – TRP-d5) and subsequently generated
deuterium labeled product (deuterated serotonin – 5HT-d4)
(Figure 6A). BON (human pancreatic carcinoid) cell line was
a gift from Dr. Courtney M. Townsend (University of Texas,
Galveston, TX, USA) and cultured as previously described (Tran
et al., 2004). Cells were seeded overnight in 96-well plates at
1.2 × 105 cells per well in 200 µL growth media containing 1%
FBS, and incubated at 37◦C, 5% CO2. After 24 h, cell media was
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exchanged for 100 mL serum-free media. All reagents added to
the cells in subsequent steps were diluted in serum-free media.
Cells were treated with 25 µL of either compound or DMSO
vehicle (1 % v/v) for 15 min at 37◦C, 5% CO2 and then treated
with 25 µL 196 mM deuterated-tryptophan (Isotec, UK) for
a further 2 h at 37◦C, 5% CO2. BON cell lysates were then
prepared by removal of all media with subsequent addition of
250 mL HTAB. These lysates were further analyzed for D4-5-HT
content by LCMS. Cell toxicity was also assessed in BON cells
using a standard lactate dehydrogenase (LDH) assay according to
instructions.
Novel In Vivo Assessment of
Pharmacokinetics/Harmcodynamics
In vivo inhibition of newly synthesized 5-HT was assessed
by dosing dogs either acutely or chronically with compound
followed by injection of TRP-d5 and subsequent 5-HT-d4
(versus compound) measurement in blood. Six male beagle dogs,
2.5–7.0 years of age and 8.6–11.0 kg weight were used in this
novel, non-lethal model. The study was performed as a three-way,
three-period crossover design with two animals assigned to one of
three groups in turn (A–C in Table 1).
Three hours after the first dose TRP-d5 was injected
subcutaneously at 50 mg kg−1 as a suspension in aqueous
0.5% methyl cellulose : 0.5% (w/w) Tween 80 at a volume of
1 ml kg−1. Approximately, 1 mL aliquots of EDTA blood was
collected serially (0–100 h) from the vena cephalica and stored
at –70◦C for analysis. A 3-week washout period was applied
before re-assignment of groups for the next period.
On the day of analysis blood samples were thawed and 50 µl
aliquots were treated with 250 µl of acetonitrile containing the
analytical internal standard (SDM) on a 96-well deep well plate
for protein precipitation. The plate was shaken vigorously and the
supernatant (200 µl) was separated by centrifugation, evaporated
to dryness under nitrogen and the pellets were resuspended
in 125 µl of water. Calibration standards were prepared in
control dog blood and processed simultaneously with the study
samples. The processed samples were analyzed by LC-MS/MS
in a Sciex API 5500 mass spectrometer coupled with a Waters
Acquity UPLC. The chromatography was employed on a Waters
Atlantis dC18 analytical column, 100 mm × 2 mm, 3.5 µm
at 50◦C. The mobile phase A was aqueous 0.1% formic acid
and the mobile phase B was methanol. The gradient program
was as follows: 0–0.8 min 2% B, 0.8–1.8 min 2% to 90% B,
1.8–2.5 min 90% B, 2.5–2.6 min 90%–2% B. The flow rate
was 0.5 ml min−1 and the sample injection volume was 5 µL.
The mass spectrometer was operated in positive electrospray
ionization mode and the analyte was detected using multiple
reaction monitoring (MRM) transitions at m/z for 181 > 164
for 5HT-d4 and 311 > 165 for SDM. The synthetic 5HT-d4
with deuterium-labeling at different positions to the 5HT-d4
produced from TRP-d5 was used for the analytical reference
due to their commercial availability. Because both forms of
5HT-d4 behaved almost identical on LC and were monitored
using the same MRM transition for the loss of ammonia, the
quality of the analytical results was considered appropriate.
The analyte peak area was quantified against the calibration
curves established in the same analytical run using Analyst 1.6
software. The lower limit of quantification was established at
0.4 ng ml−1.
For analysis of NVS-TPH120, samples were processed in a
manner similar to that for 5HT-d4. After protein precipitation
with acetonitrile the supernatant (250 µl) was separated by
centrifugation and further diluted with 50 µL of water. The
processed samples were analyzed by LC-MS/MS in a Sciex
API 4000 mass spectrometer coupled with a Waters Acquity
UPLC. The chromatography was employed on a Waters Acquity
BEHdC18 analytical column, 50 mm × 2 mm, 1.7 µm at 50◦C.
The mobile phase A was aqueous 0.1% formic acid and the mobile
phase B was methanol. The gradient program was as follows:
0-0.5 min 5% B, 0.5-1.0 min 5% to 95% B, 1.0–1.5 min 95% B,
1.5–1.6 min 95%–5% B. The flow rate was 0.6 ml min−1 and the
sample injection volume was 10 µl. The mass spectrometer was
operated in negative electrospray ionization mode and the analyte
was detected using MRM transitions at m/z for 429 > 385 for
NVS-TPH120 and 309 > 215 for SDM. The analyte peak areas
were quantified against the calibration curve established in the
same analytical run using Analyst 1.6 software. The lower limit of
quantification was established at 46 nM.
Plasma protein binding of NVS-TPH120 in dog plasma was
measured by equilibrium dialysis using RED device (Thermo).
Plasma was 10-fold diluted with water and spiked with NVS-
TPH120 at 5 µM for incubation. The obtained unbound fraction
fu’ was converted to the corresponding unbound fraction fu in
undiluted plasma using the formula fu = 1 (D ∗ (1 fu’−1 – 1 + 1
D−1))−1 where D is the dilution factor of 10.
TABLE 1 | Canine model design.
Group Dosing: oral gavage, 0.5% MC : 0.5% (w/w) Tween 80,
4 mL kg−1, 5 h intervals
A veh veh veh
B NVS-TPH120
100 mg kg−1
veh veh
C NVS-TPH120
100 mg kg−1
NVS-TPH120
100 mg kg−1
NVS-TPH120
100 mg kg−1
Three-way, three-period crossover design with two animals assigned to one of
three dose groups in turn.
TABLE 2 | Evolution of TPH1 inhibitors.
TPH-1 TPH-2
Compound IC50 (µM) SD IC50 (µM) SD
(1) pCPA 4.490 0.790 1.55 0.51
(2) LP533401 0.103 0.038 0.032 0.006
(3) NVS-TPH146 0.271 0.040 >10 n/a
(4) NVS-TPH176 0.174 0.038 >10 n/a
(5) NVS-TPH180 0.039 0.018 >10 n/a
(6) NVS-TPH120 0.021 0.009 >10 n/a
Biochemical assay potencies on TPH-1 versus TPH-2. Examples 1–2 represent
control orthosteric inhibitors. Examples 3–6 represent allosteric inhibitors of
increasing TPH1 potency yet inactive on the TPH2 isoform.
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FIGURE 1 | Identification of selectivity for TPH1 over TPH2. Compounds pCPA (A), LP533401 (B) and NVS-TPH146 (C) were pre-incubated with hTPH1 and
hTPH2 enzymes for 15 min. Reactions were initiated with the addition of the substrates BH4 and Tryptophan. The reactions were quenched with the addition of 30%
Sulfuric Acid at 30 min for hTPH1 and 60 min for hTPH2. The plates were read immediately with a PerkinElmer Envision reader (excitation = 280, emission = 535).
Animal Welfare and Ethics Statement
Animals used in these studies were housed and cared for
throughout the experiment in accordance with Swiss Animal
Welfare regulations (and in accordance to Directive 2010/63/EU)
as they were performed in Switzerland. Study protocols were
also assessed by the Novartis Institutes for Biomedical Research
ethical review panel, to ensure conformation to the UK Animals
(Scientific Procedures) Act 1986. Overnight fasting was applied
before each experimental leg and food was returned 4 h after
administration. All animals had free access to water before and
throughout the experimental period. All procedures used were as
humane as possible and complied with the recommendations of
ARRIVE (Animal Research: Reporting In vivo Experiments).
Data Analysis and Statistical Procedures
Biochemical, cell and in vivo data were analyzed via Graphpad
Prism (version 5; La Jolla, CA, USA). Biosensor data were
evaluated using Biaevaluation software (GE Healthcare).
Mechanism of action analytics were carried out using the
Enzyme Kinetics module of SigmaPlot (V12.1). Pharmacokinetic
parameters were calculated by non-compartmental method
using Phoenix (Pharsight). In vitro cell data and in vivo data are
presented as mean ±SEM. Ex vivo 5HT-d4 concentrations in the
NVS-TPH120-treated group were normalized for those in the
control group at each time point in the same session. One-way
ANOVA was used for comparison between groups followed by
Dunnett post hoc test which compared each of the NVS-TPH120
dosed groups with the control group – data represented as a
percentage reduction.
Materials
Biochemical assay buffer reagents were purchased from
Sigma–Aldrich (Poole, UK). Protein preparation reagents were
purchased from Roche (Basel, Switzerland) and purification via
Ni-NTA from Qiagen (Hilden, Germany). LDH cell toxicity assay
was purchased from Pierce (Thermo Scientific). For Biacore
experiments, L-Trp was purchased from Sigma–Aldrich (Poole,
UK), BH2 was purchased from Schirks Laboratories (Jona,
Switzerland). EZ-link Sulfo-NHS-LC-LC-Biotin was purchased
from Fisher Scientific (Loughborough, UK). All other buffer
reagents were purchased from Sigma–Aldrich (Poole, UK).
Cell assay culture plates were purchased from Fisher Scientific
(Loughborough, UK). Deuterated-tryptophan was purchased
from Isotec (Southport, UK) and HTAB was purchased from
Sigma-Aldrich (Poole, UK). L-tryptophan-2′,4′,5′,6′,7′-d5
(TRP-d5), methylcellulose, 1500 cP (MC), sulfadimethoxin from
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FIGURE 2 | Surface Plasma Resonance (SPR) sensorgrams for the
interaction of TPH1 with various ligands. Ligand (L-Tryp – blue) and
compound (LP533401 or NVS-TPH146 – red) were injected singularly or in
combination (green). Comparison of the resulting equilibrium responses
between the individual or simultaneous injection allowed the classification of
their binding mode for LP533401 (A) and NVS-TPH146 (B).
Sigma–Aldrich (Poole, UK) and serotonin-α, α,β,β-d4 (5HT-d4)
from Qmx Laboratories (Dunmow, UK) were used for in vivo
studies.
RESULTS
Evolution in Potency and Selectivity of
Allosteric TPH1 Inhibitors
Biochemical assays for TPH1 and TPH2 were used to assess
increases in potency and selectivity for our emerging chemical
series. Initially, dual TPH inhibitors were assessed for potency on
both TPH1 and TPH2 in our assays. Relative IC50 values of 4.49
and 1.55 mM were revealed for pCPA on TPH1 vs TPH2. Values
for the Lexicon next generation TPH inhibitor (LP533401) were
0.103 and 0.032 mM on TPH1 vs. TPH2, respectively. Selectivity
was first observed in the original high throughput screen hit
NVS-TPH146, with TPH1 : 2 ratio of 0.271 : 10 mM (Table 2 and
Figures 1A–C). Subsequent molecules (NVS-TPH176, -TPH180,
and -TPH120) demonstrated incremental improvements in
TPH1 potency (0.174, 0.039, and 0.021 mM) without erosion of
TPH2 selectivity (>10 mM) (Table 2). Early, less potent examples
within the chemical series were sufficiently potent to demonstrate
selectivity and the novel binding mode. The advances in potency
achieved with TPH120 enabled later in vivo experiments.
Biophysical Characterization of the
Allosteric Site
Do determine how and where the novel inhibitor class
was binding, biophysical characterization of the site was
performed. Surface plasma resonance (BiaCore) was used to
confirm the allosteric versus orthosteric nature of NVS-TPH176
versus LP533401. The comparison of the resulting equilibrium
responses between the individual or simultaneous injection of
two ligands allows the classification of their binding mode.
The obtained responses for the simultaneous injection of
LP533401 and L-Trp is lower than the sum of individual
injections. This suggests a competitive binding of both ligands
(Figure 2A). The resulting equilibrium response for the
simultaneous injection of NVS-TPH146 and L-Trp is comparable
to the sum of the responses from single injections. This indicates
that NVS-TPH146 and L-Trp bind simultaneously to TPH1
(Figure 2B). Comparable modes of inhibition for NVS-TPH146
were shown in studies co-injecting BH-2 co-factor and/or L-Trp
(Supplementary Figure S1). The region of the novel allosteric
site on TPH1 is shown in Figure 3A versus the orthosteric site
where substrate, cofactor and Fe2+ bind. The residue interaction
profile within the allosteric site is also revealed (Figure 3B).
Sequence comparisons within the allosteric pocket show subtle
differences between all isoforms (Supplementary Figure S2).
Kinetic Analysis of Inhibition
To better understand how the novel class of molecules
antagonized TPH1, kinetic analysis was carried out. Detailed
mechanism of inhibition studies were carried out with purified
truncated protein, by varying both tryptophan and BH4
concentrations in the presence of fixed concentrations of
inhibitor. When tryptophan concentration was varied in the
presence of a fixed sub-saturating concentration of BH4,
NVS-TPH180 showed a mixed mode of inhibition indicated by
the convergence of lines close or just above the x-axis on the
double reciprocal plot when fitted globally using a non-linear
regression fit based on partial mixed mode of inhibition for
a single substrate inhibitor. NVS-TPH180 also demonstrated a
strong preference for the tryptophan bound complex as indicated
by its alpha factor being 0.273 (Figure 4A). Competition studies
with BH4, using a sub-saturating concentration of tryptophan
(10 µM), also shows that NVS-TPH180 displays characteristics of
a mixed partial inhibitor when fitted globally using a non-linear
regression fit based on partial mixed mode of inhibition for a
single substrate inhibitor. The alpha value of 1.1 is also indicative
of a small (non-significant) preference towards the free enzyme
(Figure 4B). Re-plot methods looking at the dependence of Vmax
and Vmax/Km (data not shown) against inhibitor concentrations
also show very similar hyperbolic relationships re-confirming
that this compound behaves in a mixed/ non-competitive manner
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FIGURE 3 | Location of the novel TPH1 allosteric inhibitory site. The TPH1 protein is shown in gray ribbon with the catalytic site Iron and cofactor shown. The
allosteric site is indicated by the brown solvent accessible surface (A). The TPH1 protein residues that form close contacts with the allosteric ligands are shown in
atom-type colored capped sticks with the site indicated by the transparent surface (B).
FIGURE 4 | Mechanism of action of allosteric inhibitors. Double reciprocal plots of initial velocities at various concentration of the inhibitor NVS-TPH180 with
varying (A) tryptophan concentration at a fixed non-saturating concentration of BH4 (10 µM) and (B), varying BH4 at fixed non-saturating concentrations of
tryptophan (10 µM). The inhibitor concentrations (l) used are as indicated in the graph and are represented in µM concentrations. Data is a mean ± SD from a single
experiment, with each point in triplicate. Data was analyzed using Sigmaplot and fitted to a global fit analysis. Best fit anaylsis indicates a mixed partial inhibition with
tryptophan with an α-value of 0.477 indicating a preference for the tryptophan bound complex.
with relative Ki values of 64 and 74 nM, and Km values of 13 and
11 µM, respectively, for both tryptophan and BH4 (Figure 4).
Cell Activity of Allosteric TPH1 Inhibitors
Whole cell activity of TPH1 inhibition was assessed using
BON cells (human carcinoid cell line) within a newly designed
in vitro assay where new synthesiszed 5-HT could be detected via
the labeling of tryptophan substrate with deuterium. LP533401
registered an IC50 of 12.4 mM, whereas a value for pCPA could
not be established. The early allosteric inhibitor NVS-TPH176
registered 27.2 mM, whereas a>30-fold improvement in potency
to 0.8 mM was observed with NVS-TPH120 (Figure 5). No
impact on cell viability was detected for any compound up to
30 mM, assessed by LDH assay (Figure 5B).
Inhibition of De Novo Synthesis of
Serotonin by NVS-TPH120 In Vivo
The degree to which in vitro inhibitory characteristics could
be translated into animals, we developed an in vivo test
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system. Serotonin has long elimination half-lives in blood
which hampers early and robust detection of reduced rate of
serotonin synthesis. Furthermore, sequence and biochemical
potency species cross-reactivity analysis indicated a drop-off in
alignment in rodents (Supplementary Figure S3). To overcome
this challenge, we developed a novel in vivo mechanistic
model using a deuterium-labeled tryptophan and monitoring
its metabolic conversion to the deuterated serotonin which can
be discriminated from native serotonin by LC-MS/MS analysis
(Figure 6A). NVS-TPH120 was dosed to dogs orally once or
three times with 5 h intervals between the doses. TRP-d5 was
injected s.c. 3 h after the first dose. In the 1 × 100 mg kg−1
group NVS-TPH120 blood concentrations reached a Cmax of
82 ± 38 µM at 2.3 ± 0.5 h (0.7 h before the TRP-d5 injection)
followed by a monophasic decay at a mean elimination half-life
of 7.7± 5.2 h (Figure 6C). Following 3× 100 mg kg−1 dosing of
NVS-TPH120 a peak concentration of 109± 40 mM was reached
at 11.0 ± 1.1 h. The 3 × 100 mg kg−1 group achieved the mean
AUC 3.3-fold higher than that after 1 × 100 mg kg−1 dosing.
The synthesis of 5HT-d4 was inhibited in a dose-dependent
manner although significant efficacy was not observed until 29 h
(Figure 6B). The lowered level of 5HT-d4 was sustained up to
104 h after the first dosing of NVS-TPH120 in the 3× 100 mg/kg
group. The in vitro IC50 for the inhibition of dog TPH1 by
NVS-TPH120 was scaled to the corresponding whole blood IC50
taking into account plasma protein binding. Due to very high
plasma protein binding (fu= 0.0018) the corrected IC50 for blood
was increased to 23 µM. The NVS-TPH120 concentration was
maintained above the scaled IC50 up to 12 h post compound
dosing at 1× 100 mg kg−1 while the 3× 100 mg kg−1 treatment
exceeded this blood concentration for up to 32 h (Figure 6D).
DISCUSSION AND CONCLUSION
Knockout studies have demonstrated the distribution of TPH
isoforms in the body – TPH1 primarily expressed in the pineal
gland and enterochromaffin cells of the gut, whereas TPH2 is
restricted to neuronal cells (Cote et al., 2003; Walther et al., 2003;
Patel et al., 2004). A breakthrough in pharmacologic inhibition
of TPH was achieved with the discovery of molecules whose
expanded pCPA core gained selectivity over related amino acid
hydroxylases (phenylalanine and TH). Selectivity over TPH2
was effectively achieved through restricted distribution to the
gut, including exclusion of enteric nerves (Shi et al., 2008;
Margolis et al., 2014), providing both pre-clinical and clinical
evidence for promising therapeutic options for gut-related
disorders such as non-constipating irritable bowel syndrome
(Brown et al., 2011; Kim et al., 2015). However, diseases
in which pathogenesis is driven by TPH1 over expression,
and subsequent 5-HT production, in peripheral tissues remain
beyond the reach of these next generation inhibitors. Effective
TPH1 inhibition beyond the gut requires pharmacologic
selectivity over TPH2, and therefore a different chemical strategy
entirely.
The TPH1-specific allosteric binding site described in these
studies relies both on the robust, inventive nature of the
FIGURE 5 | BON (human carcinoid cell) cell responses to TPH1
inhibitors. (A) Inhibition of D4-5-HT production. Compounds were incubated
with BON cells for 15 min prior to addition of deuterated substrate. After 2 h
intracellular D4-5-HT was extracted and quantified using LCMS/MS. (B) Table
of compound efficacy vs. cell toxicity IC50 data. The data are expressed as
means ± SEM; (n = 3).
assay systems used to investigate this novel biology, and
on the availability of well characterized tool compounds for
comparison. Literature characterization of pCPA and LP533401
have measured TPH1 activity at 250 and 0.7 mM IC50 values,
respectively, (Liu et al., 2008). These differ from the values
reported here by approximately 50- and 7-fold, respectively,
revealing a higher degree of sensitivity to inhibition within the
biochemical assay system described in each study. A 17-fold drop
in potency is observed in the BON cell assay for LP533401 (pCPA
effect not measurable above 30 mM without apparent toxicity).
These data contrast previous reports which suggest a greater
potency in the rat mastocytoma line RBL-2H3 than that seen
biochemically – surprising discrepancies which may be based
upon differing species and/or undetected/mild cell toxicity (Liu
et al., 2008). Early allosteric inhibitors showed a biochemical
and cell profile superior to pCPA, yet inferior to LP533401. The
inhibitory potential of the allosteric pocket was only revealed in
later examples (e.g., NVS-TPH120) which demonstrated 13- and
15-fold improvements over LP533401 in biochemical and cell
potencies, respectively.
LP533401 was evolved from a common pCPA core, and thus
the demonstration of an equivalent tryptophan substrate binding
site could be anticipated and was confirmed in our BiaCore
experiments (Cianchetta et al., 2010). The apparent chemical
diversity of early inhibitor examples identified within our
biochemical screen opened the possibility of a different binding
mode. This hypothesis was supported by biochemical selectivity
over TPH2 ->37-fold with the initial NVS-TPH146 compound,
improving to >476-fold with NVS-TPH120. BiaCore studies
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FIGURE 6 | In vivo Inhibition of de novo synthesis of 5HT-d4 by NVS-TPH120. The study was conducted as a 3-way crossover design. Male beagle dogs
received orally vehicle or NVS-TPH120 2 h before and 3 h and 8 h after subcutaneous injection of TRP-d5 at 50 mg kg-1 (n = 6). Serially bled samples were analyzed
by LC-MS/MS. (A) Metabolic pathway of TRP-d5 conversion to 5HT-d4. (B) Real values of blood 5-HT-d4 recovered from blood (baseline subtracted). (C) Blood
5HT-d4 levels % relative to the vehicle group. ∗P < 0.05; ∗∗P < 0.01. (D) Blood pharmacokinetic profiles of NVS-TPH120 (n = 6). AAAD: aromatic L-amino acid
decarboxylase. The data are expressed as means ± SEM.
provided the first real evidence of a novel allosteric binding site,
when NVS-TPH146 and tryptophan ligand/co-factor were able to
bind simultaneously – data further confirmed by the resolution
of co-crystals containing NVS-TPH176 (data not shown due
to proprietary nature of compound structure). The location of
the allosteric site suggests the potential to influence orthosteric
binding from the opposite side of the protein, as indicated by
a common sequence of alpha helix (Supplementary Figure S2).
Though there are subtle sequence differences in the allosteric site
between each isoform, the exact mechanism by which selectivity
for TPH1 is obtained with the novel inhibitors will likely require
dynamic analytics to reveal. Mechanism of action experiments
further demonstrated the lack of competitive binding to the
substrate site, yet also suggested a preference for the tryptophan
bound complex as indicated by its alpha factor being 0.273. This
was reconfirmed by using re-plot methods in which we observed
a larger titration in our Vmax versus inhibitor concentration
plot as compared to our Vmax/Km plots - indicating that the
inhibitor, although able to bind free enzyme at a low affinity,
has a much higher preference and affinity for the substrate
bound complex. This is consistent with X-ray data that shows the
inhibitor binding to an area distal from the substrate binding site
and suggests that this allosteric site becomes more accessible once
the tryptophan binds. The alpha value of 1.1 for BH4 co-factor is
also indicative of a small (non-significant) preference towards the
free enzyme. Again, re-plot methods looking at the dependence
of Vmax and Vmax/Km against inhibitor concentrations also
show very similar hyperbolic relationships re-confirming that
NVS-TPH180 behaves in a way entirely consistent with the X-ray
observations that show a binding site distal to where BH4 resides.
In both double-reciprocal plots, a beta value of less than one is
generated, which indicates partial inhibition. However, it must be
recognized that these assays are closed systems and as such one
reasons for apparent partiality could be due to the time for the
right complex to form, to allow the inhibitor to exert its full affect.
Once it forms the final complex, the inhibitor does not come off
until both substrates come off, also contributing to the final affect.
Further evidence of partiality is in vivo, where inhibition of newly
synthesized 5-HT plateaus at approximately 50% (Figure 6).
Deuterium-labeled tryptophan was also used in vivo as a
novel method by which specifically new synthesized 5-HT could
be monitored. The system was successfully validated in rat,
rabbit and dog using pCPA as a reference TPH inhibitor (data
not shown). Comparative species homology of TPH1 decreases
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from human to rat – differences which impacted the degree to
which allosteric molecules inhibited TPH1 – demonstrated by
NVS-TPH120 within biochemical assays with different species
proteins (Supplementary Figure S3). Comparable potency and
efficacy was observed between human and dog proteins with
NVS-TPH120 and thus further in vivo studies used dogs.
TPH1 inhibited via the allosteric site showed significant efficacy,
peaking at 50%, which was sustained up to 100 h post tryptophan
injection. Significant inhibition was not observed until 29 h as
reflected by the delay in the increase of blood 5HT-d4 levels.
The next steps in the evolution of this chemotype of allosteric
inhibitors is the resolution of eroded rodent cross reactivity
and high plasma protein binding. Improvements in these
areas would provide a tool by which more direct assessment
of efficacy upon 5-HT-mediated complex remodeling diseases
of the periphery could be made – an example of which
could be the rodent hypoxia/SUGEN model of PAH which
demonstrates increased TPH1 expression and 5-HT production,
and is also sensitive to pCPA inhibition (Ciuclan et al., 2013;
Thomas et al., 2013). Increased pulmonary artery endothelial
cell (PAEC) TPH1 expression in PAH patients together with
increased SERT expression in pulmonary artery smooth muscle
cells (PASMC), may induce the hyperplasia central to PAH
(Eddahibi et al., 2006). TPH1 knockout animals are protected
from chronic hypoxia-induced pulmonary vascular remodeling
and hypertension, although RV indices remain uninfluenced
(Morecroft et al., 2007). PAEC:PASMC communication via
5-HT may not necessarily be paracrine, as demonstrated by
co-culture studies investigating the role of 5-HT and TGFb
signaling through myoendothelial gap junctions to effect PASMC
differentiation (Gairhe et al., 2012). The pathologic disease
relevance of PAEC-derived 5-HT was further investigated in
selective in vivo gene therapy studies. Adenoviral vectors targeted
to PAECs (utilizing bispecific antibody to angiotensin-converting
enzyme (ACE) as the selective targeting system) were used to
deliver small hairpin Tph1 RNA sequences in rats. Hypoxic rats
increased lung Tph1 expression leading to the development of
PAH pathologies, both of which were attenuated by PAEC-Tph1
gene knockdown (Morecroft et al., 2012). A recent publication by
Abid and colleagues suggested combined gut and lung inhibition
with LP533401. It is conceivable that a profound reduction in the
whole body burden of 5-HT may impact peripheral pathology
as the primary source of 5-HT is the gut (>95% in healthy
individuals) which is then stored in platelets in circulation
(Walther et al., 2003). However, the hypothesized inhibition of
lung TPH1 by LP533401 was based on lung measures containing
5-HT-devoid platelets. In addition, the surprising lack of pathway
activation within the chronic hypoxia model used questions the
validity of serotonin pathway involvement / analytics (Abid et al.,
2012).
The clinical applicability of effective, selective TPH1 inhibition
in peripherial tissues beyond the gut does not end with PAH.
Recent transcripome analysis has found an association between
Bmpr1a deletion in mice and increased TPH1 expression in
pancreatic islets, revealing a potentially important role for
pancreatic 5-HT production in β-cell insulin production and
glucose homeostasis (Jiang et al., 2015). These data are supported
by studies in which Tph1-deficient mice fed a high-fat diet
are protected from obesity, insulin resistance and nonalcoholic
fatty liver disease while exhibiting greater energy expenditure
by brown adipose tissue (Crane et al., 2015). Mechanistic
evidence for 5-HT production, storage and release by T cells
(particularly CD8+) is emerging which may bear relevance to
an array of immune functional consequences in either health or
disease (Chen et al., 2015). Furthermore, mast cell expression
of TPH1, release of 5-HT and subsequent bronchoconstriction
has been demonstrated in mice responding to allergen and
IL-33, suggesting a pathologic role in the lung tissue of allergic
asthmatics (Ahern, 2011; Sjöberg et al., 2015).
Thus, emerging evidence supports a role for TPH1 at the site
of pathogenesis in complex remodeling, metabolic or immune
diseases of peripheral tissues, and therefore necessitates a safe
means of inhibition for effective therapy beyond the gut, yet
without unwanted CNS effects. Here we describe a novel binding
site on TPH1 to which the first molecules to achieve selectivity
over TPH2 bind. The novel biologic systems generated to study
these inhibitors also provide confidence that a major step forward
has been taken in the development of a new class of safe
peripheral serotonergic drugs.
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FIGURE S1 | Kinetic analysis of inhibitors binding to TPH1 (A) Determination
of the kinetic parameters of NVS-TPH146 binding to TPH1 (B) Determination of
the kinetic parameters of LP533401 binding to TPH1 (C) Equilibrium response for
the individual versus simultaneous (blue) injection of BH2 (red) and L-Trp (green) is
comparable to the sum of the responses from single injections. (D) Equilibrium
response for the individual or simultaneous (blue) injection of NVS-TPH146 (green)
or BH2 + L-Trp (red).
FIGURE S2 | Sequence alignment of amino acid hydroxylases TH, PH,
TPH1, and TPH2. RCSB protein databank was used to obtain the human protein
structures and sequences and EMBL for their Cluster Omega multi sequence
alignment. Regions of the orthosteric site are shown in green and the allosteric site
in blue, based upon residue interaction points (shown Figure 3).
FIGURE S3 | Percentage sequence homology table between species for
TPH1 (A). Activity of NVS-TPH120 across the TPH1 assay using protein from
different species (B). Reactions were initiated with the addition of the substrates
BH4 and Tryptophan. The reactions were quenched with the addition of 30%
Sulfuric Acid at 30 min for hTPH1 and 60 min for hTPH2. The plates were read
immediately with a PerkinElmer Envision reader (excitation = 280,
emission = 535).
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